August 11, 2026 – MoonLake Immunotherapeutics has announced a significant breakthrough in the treatment of psoriatic arthritis (PsA), with its investigational drug, sonelokimab, successfully meeting the primary endpoint in the pivotal Phase III IZAR-1 trial. This positive readout, which demonstrated substantial clinical benefit in biologic-naïve adult patients with active PsA, follows closely on the heels of promising data for sonelokimab in hidradenitis suppurativa (HS), further bolstering the company’s therapeutic pipeline and offering renewed hope for patients grappling with these chronic inflammatory conditions.
The IZAR-1 trial, which enrolled patients who had not previously received biologic therapies, revealed that 42.1% of participants treated with the 60mg dose of sonelokimab achieved an American College of Rheumatology 50 (ACR50) response at week 16. This endpoint signifies a substantial improvement in disease activity, a critical measure in the management of PsA. The success in this crucial trial marks a pivotal moment for MoonLake, positioning sonelokimab as a potential new contender in the PsA treatment landscape.
Psoriatic arthritis is a complex and debilitating chronic inflammatory condition characterized by the immune system mistakenly attacking healthy tissues. This autoimmune response primarily affects the joints, leading to pain, swelling, and stiffness, but can also impact areas where tendons attach to bone. Beyond the musculoskeletal manifestations, PsA often coexists with skin psoriasis, further compounding the physical and emotional burden on patients. The condition can significantly impair quality of life, affecting daily activities, work, and social engagement.
A Look at the IZAR-1 Trial: Efficacy Across Multiple Domains
The IZAR-1 trial (NCT06641076) was meticulously designed to assess the efficacy and safety of sonelokimab in a patient population that represents a broad spectrum of active PsA. The trial’s primary endpoint, the ACR50 response rate at week 16, was successfully met, indicating a clinically meaningful reduction in disease activity for a significant portion of the treated patients.
Beyond the primary endpoint, the trial also showcased compelling results across several key secondary clinical endpoints. A remarkable 66.5% of patients achieved an ACR20 response, signifying at least a 20% improvement in tender and swollen joint counts, as well as other disease parameters. Furthermore, 41.2% of patients attained Minimal Disease Activity (MDA), a state characterized by a low level of disease activity, and 61% achieved a Psoriasis Area and Severity Index 90 (PASI90) response, indicating a substantial improvement in skin lesions associated with psoriasis. The achievement of PASI90 is particularly noteworthy, as it demonstrates sonelokimab’s potential to address the dermatological component of PsA concurrently with its joint effects.
The positive impact of sonelokimab extended to patient-reported outcomes and functional measures. Significant improvements were observed from baseline in the Health Assessment Questionnaire Disability Index (HAQ-DI), a measure of physical function and disability, with a mean change of -0.427. This reduction indicates a notable decrease in the limitations experienced by patients in their daily lives. Additionally, the SF-36 Physical Component Summary (PCS) score, which assesses physical health-related quality of life, showed improvement with a score of 6.54, suggesting enhanced physical well-being among those treated with sonelokimab.
Building Momentum: Chronology of Sonelokimab’s Development
The journey of sonelokimab has been characterized by strategic development and a consistent focus on delivering robust clinical data. MoonLake Immunotherapeutics has pursued a dual-pronged approach, investigating the drug’s potential in both psoriatic arthritis and hidradenitis suppurativa.
The success in the IZAR-1 PsA trial builds upon earlier positive readouts for sonelokimab in hidradenitis suppurativa (HS) earlier in 2026. In the VELA-1 and VELA-2 trials (NCT06411899 and NCT06411379, respectively), a significant proportion of patients treated with sonelokimab achieved substantial clinical responses. Specifically, 62% of patients achieved a Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at week 40, and an impressive 32% reached HiSCR100, indicating near-complete resolution of HS lesions. Furthermore, sonelokimab demonstrated the ability to induce inflammatory remission in 25% of patients, defined by MoonLake as a complete clearance of abscesses, nodules, and draining tunnels – a critical goal in HS management. These promising HS data led MoonLake to confirm its intention to file for sonelokimab’s approval in HS in the second half of 2026, targeting a market estimated by GlobalData to reach $7.8 billion by 2034.
The momentum gained from the HS data has now translated into a significant advancement in the PsA program. The IZAR-1 trial represents a crucial step in validating sonelokimab’s efficacy in a distinct but related inflammatory pathway. Patients enrolled in IZAR-1 will continue to receive treatment or placebo for a total of 52 weeks, with the aim of evaluating the durability of sonelokimab’s effects. This long-term data is anticipated in the first half of 2027, which will be vital for understanding the sustained benefits of the drug.
MoonLake is also actively investigating sonelokimab in PsA through the IZAR-2 trial (NCT06641089). This trial differentiates itself from IZAR-1 by including a comparison arm against a standard of care (SoC) treatment, specifically AbbVie’s Skyrizi (risankizumab). IZAR-2 is designed to evaluate sonelokimab in patients with active PsA who have demonstrated an inadequate response to anti-TNFa therapies, a key patient segment often requiring alternative treatment options. Enrollment for IZAR-2 is expected to be completed in the third quarter of 2026, promising further insights into sonelokimab’s comparative efficacy.
Supporting Data and Clinical Significance
The efficacy signals observed in the IZAR-1 trial are underpinned by a robust set of data points that highlight sonelokimab’s multifaceted impact on PsA. The achievement of ACR50, ACR20, and MDA, alongside the significant PASI90 response, collectively paints a picture of a drug that can simultaneously address the inflammatory, joint, and skin manifestations of PsA.
The observed improvements in HAQ-DI and SF-36 PCS scores are particularly important as they directly translate to tangible benefits in patients’ daily lives. Reduced disability and improved physical functioning are paramount for individuals living with chronic conditions like PsA, enabling them to engage more fully in work, social activities, and personal pursuits.
The mechanism of action of sonelokimab, targeting IL-17A and IL-17F cytokines, is a well-established pathway in inflammatory diseases. Dr. Jorge Santos da Silva, founder and CEO of MoonLake, emphasized this biological rationale, stating, "These data are also encouraging as they are consistent with what was previously observed in other IL-17A/F programmes." This consistency suggests a predictable and potentially potent therapeutic effect, aligning with the understanding of the inflammatory cascade in PsA.
MoonLake’s strategic emphasis on simultaneous improvement across multiple clinically relevant endpoints is a testament to their patient-centric approach. "We are particularly encouraged by the strong efficacy observed across multiple clinically relevant endpoints simultaneously, which has been our focus," Dr. Santos da Silva added. This holistic approach aims to provide comprehensive relief, addressing the multifaceted nature of PsA and improving overall patient well-being.
Official Responses and Future Outlook
The positive topline results from the IZAR-1 trial have been met with enthusiasm from MoonLake leadership. Dr. Jorge Santos da Silva articulated the significance of this milestone: "The positive topline results from IZAR-1 represent an important milestone for MoonLake and, more importantly, for patients living with psoriatic arthritis." He further elaborated on the drug’s potential: "MoonLake said the Phase III data supports sonelokimab as a therapy to not only address single symptoms of PsA, but also provide meaningful improvements across musculoskeletal symptoms, skin disease, patient quality of life and physical function."
The company’s confidence in sonelokimab’s broad therapeutic potential is evident in their ongoing clinical development strategy, which includes the comparative IZAR-2 trial against a leading competitor. This strategic move suggests MoonLake’s ambition to position sonelokimab as a differentiated and potentially superior treatment option.
However, the market’s reaction has been more nuanced. Despite the strong clinical data, MoonLake’s stock experienced a decline of 5% on August 10th, following the announcement. This market response, while potentially influenced by various factors, highlights the intense scrutiny and high expectations within the biopharmaceutical sector. As of market open on August 11th, the stock price continued to see a downward trend. MoonLake is listed on the Nasdaq exchange with a reported market capitalization of $1.41 billion.
Industry experts have also weighed in on the competitive landscape. Dr. Christopher Ritchlin, professor of medicine and chief of allergy, immunology, and rheumatology at the University of Rochester Medical Center, previously commented to Clinical Trials Arena that sonelokimab would face a challenging market in PsA, particularly against established therapies like UCB’s Bimzelx (bimekizumab). Dr. Ritchlin emphasized the need for sonelokimab to differentiate itself through superior efficacy or a more favorable cost profile to gain significant market share. The upcoming comparative data from IZAR-2 will be crucial in addressing these competitive concerns.
Implications for the PsA Market and Beyond
The potential approval of sonelokimab for psoriatic arthritis could have significant implications for the treatment paradigm. The PsA market is a substantial and growing sector, with GlobalData forecasting it to be worth $13.5 billion by 2033 across the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan), an increase from $9.5 billion in 2023. The introduction of a new therapy with a demonstrated ability to improve multiple disease domains could offer a valuable alternative for patients who are inadequately managed by existing treatments.
The dual success of sonelokimab in both PsA and HS underscores the potential of this molecule to address a range of IL-17-mediated inflammatory conditions. This broad applicability enhances its strategic value for MoonLake and offers a compelling narrative for its long-term development. As the company continues to progress through late-stage clinical trials and moves towards potential regulatory submissions, the coming years will be critical in determining sonelokimab’s ultimate impact on patient care and its standing within the competitive biopharmaceutical landscape. The upcoming 52-week durability data from IZAR-1 and the comparative data from IZAR-2 will be closely watched by clinicians, patients, and investors alike, shaping the future trajectory of MoonLake Immunotherapeutics and the treatment of psoriatic arthritis.
About the Author
